ObjectiveTo evaluate the clinical effect and safety of Apatinib combined with Tegafur as second line treating advanced gastric cancer.Methods28 patients with advanced gastric cancer treated in the department of internal medicine-oncology of our hospital from December 2015 to February 2017 were selected and randomly divided into observation group and control group,each group contains 14 patients.Observation group was treated with Apatinib of 500 mg,qd,and Tegafur Capsules of 40-60 mg for oral administration,bid,from day 1 to day 14 then withdrawal for one week,and 21 days were one cycles.The whole treatment lasted at least 4 cycles.Control group only received Tegafur Capsulesas second line treatment of 40-60 mg for oral administration,bid,from day 1 to day 14,then withdrawal for one week,and 21 days were one cycles.The whole treatment lasted at least 4 cycles.The treatment effect,the nutritional status,the quality of life,and the adverse reactions between the two groups were compared after treatment.ResultsThe total remission rate and disease control rate of the observation group(21.4%and 92.9%)were significantly higher than those of the control group(7.1%and 71.4%)(P＜0.01).The quality of life in the observation group was significantly lower than that in the control group after treatment(P＜0.01).The nutritional status score in the observation group was significantly better than that in the control group after the treatment(P＜0.01).The incidence of chest tightness,hypertension,proteinuria,appetite loss,nausea and vomiting,peripheral nerve toxicity and hemoglobin reduction in the observation group were significantly higher than those in the control group (P＜0.01 or P＜0.05).ConclusionThe effect and toxicity of Apatinib combined with Tegafur as second line treatment of patients with advanced gastric cancer is better,but it has more adverse reactions,and may reduce the patients′nutritional status and quality of life,thus its clinical application should be considered carefully.